Growth Hormone Upregulates Melanoma Drug Resistance and Migration via Melanoma-Derived Exosomes DOI Open Access
Prateek Kulkarni, Reetobrata Basu,

T. Bonn

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(15), P. 2636 - 2636

Published: July 24, 2024

Drug resistance in melanoma is a major hindrance cancer therapy. Growth hormone (GH) plays pivotal role contributing to the chemotherapy. Knocking down or blocking GH receptor has been shown sensitize tumor cells Extensive studies have demonstrated that exosomes, subset of extracellular vesicles, play an important drug by transferring key factors In this study, we explore how modulates exosomal cargoes from and their resistance. We treated with GH, doxorubicin, GHR antagonist, pegvisomant, analyzed exosomes released. Additionally, administered these recipient cells. The GH-treated released elevated levels ABC transporters (ABCC1 ABCB1), N-cadherin, MMP2, enhancing migration antagonism reduced levels, restoring sensitivity attenuating migration. Overall, our findings highlight novel modulating drive chemoresistance metastasis melanoma. This understanding provides insights into mechanisms suggests as potential therapy overcome treatment.

Language: Английский

Site-Selective Zwitterionic Poly(caprolactone-carboxybetaine)-Growth Hormone Receptor Antagonist Conjugate: Synthesis and Biological Evaluation DOI

Jane K. Yang,

Madeline B. Gelb, Kyle Tamshen

et al.

Biomacromolecules, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 29, 2024

Zwitterionic polymers have been found to be biocompatible alternatives poly(ethylene glycol) (PEG) for conjugation proteins. This work reports the site-selective of poly(caprolactone-carboxybetaine) (pCLZ) human growth hormone receptor antagonist (GHA) B2036-alkyne and investigation safety, activity, pharmacokinetics. Azide-end-functionalized pCLZs were synthesized conjugated GHA via copper-catalyzed click reaction. The resulting inhibitory bioactivity concentration responses in Ba/F3-GHR cells compared those PEGylated B2036. IgG IgM antibody production was tested mice, no measurable or cytokine detected pCLZ conjugate. Using

Language: Английский

Citations

1
Growth Hormone Upregulates Melanoma Drug Resistance and Migration via Melanoma-Derived Exosomes DOI Open Access
Prateek Kulkarni, Reetobrata Basu,

T. Bonn

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(15), P. 2636 - 2636

Published: July 24, 2024

Drug resistance in melanoma is a major hindrance cancer therapy. Growth hormone (GH) plays pivotal role contributing to the chemotherapy. Knocking down or blocking GH receptor has been shown sensitize tumor cells Extensive studies have demonstrated that exosomes, subset of extracellular vesicles, play an important drug by transferring key factors In this study, we explore how modulates exosomal cargoes from and their resistance. We treated with GH, doxorubicin, GHR antagonist, pegvisomant, analyzed exosomes released. Additionally, administered these recipient cells. The GH-treated released elevated levels ABC transporters (ABCC1 ABCB1), N-cadherin, MMP2, enhancing migration antagonism reduced levels, restoring sensitivity attenuating migration. Overall, our findings highlight novel modulating drive chemoresistance metastasis melanoma. This understanding provides insights into mechanisms suggests as potential therapy overcome treatment.

Language: Английский

Citations

0